Quick Answer
CONMED Corp reported R&D Expense of $55.88 million for fiscal year 2025.
CONMED Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $55.88M | +2.7% |
| 2024 | $54.43M | +3.5% |
| 2023 | $52.60M | +11.6% |
| 2022 | $47.15M | +8.2% |
| 2021 | $43.56M | +7.6% |
| 2020 | $40.47M | -11.0% |
| 2019 | $45.46M | +7.8% |
| 2018 | $42.19M | +30.6% |
| 2017 | $32.31M | +0.2% |
| 2016 | $32.25M | +17.6% |
| 2015 | $27.44M | -1.2% |
| 2014 | $27.78M | +7.5% |
| 2013 | $25.83M | -8.4% |
| 2012 | $28.21M | -1.5% |
| 2011 | $28.65M | -3.4% |
| 2010 | $29.65M | -6.9% |
| 2009 | $31.84M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.90M | +2.5% | -1.7% |
| June 30, 2025 | $14.14M | +0.3% | +9.2% |
| March 31, 2025 | $12.95M | -4.8% | -4.5% |
| September 30, 2024 | $13.56M | +8.8% | -3.8% |
| June 30, 2024 | $14.10M | +3.9% | +3.7% |
| March 31, 2024 | $13.59M | +8.4% | +9.1% |
| September 30, 2023 | $12.46M | -2.4% | -8.2% |
| June 30, 2023 | $13.57M | +18.1% | +8.2% |
- CONMED Corp showed an increase of +2.7% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, CONMED Corp’s r&d expense has grown by 75.5% (from $31.84 million to $55.88 million).
- The most recent figure is from CONMED Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: